Poly(ε-caprolactone)/eudragit nanoparticles for oral delivery of aspart-insulin in the treatment of diabetes

Journal of Pharmaceutical Sciences

Volumn 99, Issue 2, 2010, Pages 879-889

  Damgé, Christiane ^a,b   Socha, Marie ^b   Ubrich, Nathalie ^b   Maincent, Philippe ^b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Diabetes; Insulin analogues; Nanoparticles; Oral insulin; Polymer

Indexed keywords

EUDRAGIT; INSULIN ASPART; NANOPARTICLE; POLYCAPROLACTONE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; EXCIPIENT; INSULIN; METHYLMETHACRYLATE METHACRYLIC ACID COPOLYMER; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; POLYESTER; POLYMETHACRYLIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INTESTINE MUCOSA; MALE; NONHUMAN; RAT; ANIMAL; CHEMISTRY; DIGESTIVE TRACT INTUBATION; ELECTROCHEMISTRY; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE TOLERANCE TEST; METABOLISM; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; DRUG DELIVERY SYSTEMS; ELECTROCHEMISTRY; EXCIPIENTS; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INTUBATION, GASTROINTESTINAL; MALE; NANOPARTICLES; POLYESTERS; POLYMETHACRYLIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 74049130927     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21874     Document Type: Article

References (48)

1. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. 1922. Pancreatic extracts in the treatment of diabetes mellitus. Preliminary report. Can Med Assoc J 12:141-146.
2. Daneman D. 2006. Type 1 diabetes. Lancet 367: 847-858.
3. Owens DR, Zinman B, Bolli G. 2003. Alternative routes of insulin delivery. Diabet Med 20:886-898.
4. Damgé C, Pinto Reis C, Maincent P. 2008. Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv 5:45-68.
5. Liu H, Tang R, Pan WS, Zhang Y, Liu H. 2003. Potential utility of various protease inhibitors for improving the intestinal absorption of insulin in rats. J Pharm Pharmacol 55:1523-1529.
6. Morishita M, Goto T, Peppas NA, Joseph JI, Torjman MC, Munsick C, Nakamura K, Yamagata T, Takayama K, Lowman AM. 2004. Mucosal insulin delivery systems based on complexation polymer hydrogels: Effect of particle size on insulin enteral absorption. J Control Release 97:115-124.
7. Shao Z, Li Y, Chermak T, Mitra AK. 1994. Cyclodextrins as mucosal absorption promoters of insulin. II. Effects of beta-cyclodextrin derivatives on alpha-chymotryptic degradation and enteral absorption of insulin in rats. Pharm Res 11:1174-1179.
8. Mesiha MS, Ponnapula S, Plakogiannis F. 2002. Oral absorption of insulin encapsulated in artificial chyles of bile salts, palmitic acid and alpha tocopherol dispersions. Int J Pharm 249:1-5.
9. Eaimtrakarn S, Rama Prasad YV, Ohno T, Konishi T, Yoshikawa Y, Shibata N, Takada K. 2002. Absorption enhancing effect of labrasol on the intestinal absorption of insulin in rats. J Drug Target 10:255-260.
10. Clement S, Dandona P, Still JG, Kosutic G. 2004. Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: Results from a phase I/II clinical trial. Metabolism 53:54-58.
11. Kipnes M, Dandona P, Tripathy D, Still JG, Kosutic G. 2003. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care 26:421-426.
12. Xia CQ, Wang J, Shen WC. 2000. Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 295:594-600.
13. Cui F, Shi K, Zhang L, Tao A, Kawashima Y. 2006. Biodegradable nanoparticles loaded with insulinphospholipid complex for oral delivery: Preparation, in vitro characterization and in vivo evaluation. J Control Release 114:242-250.
14. Morishita M, Kamei N, Ehara J, Isowa K, Takayama K. 2007. A novel approach using functional peptides for efficient intestinal absorption of insulin. J Control Release 118:177-184.
15. Babu VR, Patel P, Mundargi RC, Rangaswamy V, Aminabhavi TM. 2008. Developments in polymeric devices for oral insulin delivery. Expert Opin Drug Deliv 5:403-415.
16. Damgé C, Michel C, Aprahamian M, Couvreur P. 1988. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 37:246-251.
17. Damgé C, Hillaire-Buys D, Puech R, Hoeltzel A, Michel C, Ribes G. 1995. Effects of orally administered insulin nanocapsules in normal and diabetic dogs. Diabetes Nutr Metab 8:3-9.
18. Foss AC, Goto T, Morishita M, Peppas NA. 2004. Development of acrylic-based copolymers for oral insulin delivery. Eur J Pharm Biopharm 57:163-169.
19. Xiong XY, Li YP, Li ZL, Zhou CL, Tam KC, Liu ZY, Xie GX. 2007. Vesicles from Pluronic/poly(lactic acid) block copolymers as new carriers for oral insulin delivery. J Control Release 120:11-17.
20. Barichello JM, Morishita M, Takayama K, Nagai T. 1999. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 25:471-476.
21. Kumar PS, Ramakrishna S, Saini TR, Diwan PV. 2006. Influence of microencapsulation method and peptide loading on formulation of poly(lactideco-glycolide) insulin nanoparticles. Pharmazie 61: 613-617.
22. Cui FD, Tao AJ, Cun DM, Zhang LQ, Shi K. 2007. Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery. J Pharm Sci 96:421-427.
23. Ma Z, Lim TM, Lim LY. 2005. Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. Int J Pharm 293:271-280.
24. Sarmento B, Ribeiro A, Veiga F, Ferreira D, Neufeld R. 2007. Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules 8:3054-3060.
25. Lin YH, Mi FL, Chen CT, Chang WC, Peng SF, Liang HF, Sung HW. 2007. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules 8:146-152.
26. Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D. 2007. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 24:2198-2206.
27. Reis CP, Ribeiro AJ, Veiga F, Neufeld RJ, Damgé C. 2008. Polyelectrolyte biomaterial interactions provide nanoparticulate carrier for oral insulin delivery. Drug Deliv 1:127-139.
28. Reis CP, Veiga FJ, Ribeiro AJ, Neufeld RJ, Damgé C. 2008. Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response. J Pharm Sci 97:5290-5305.
29. Liu J, Gong T, Wang C, Zhong Z, Zhang Z. 2007. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: Preparation and characterization. Int J Pharm 340:153-162.
30. Sarmento B, Martins S, Ferreira D, Souto EB. 2007. Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomed 2:743-749.
31. Morcol T, Nagappan P, Nerenbaum L, Mitchell A, Bell SJ. 2004. Calcium phosphate-PEG-insulincasein (CAPIC) particles as oral delivery systems for insulin. Int J Pharm 277:91-97.
32. Bhumkar DR, Joshi HM, Sastry M, Pokharkar VB. 2007. Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin. Pharm Res 24:1415-1426.
33. Damgé C, Maincent P, Ubrich N. 2007. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release 117:163-170.
34. Morales J. 2007. Defining the role of insulin detemir in basal insulin therapy. Drugs 67:2557-2584.
35. Brange J, Owens DR, Kang S, Volund A. 1990. Monomeric insulins and their experimental and clinical implications. Diabetes Care 13:923-954.
36. Setter SM, Corbett CF, Campbell RK, White JR. 2000. Insulin aspart: A new rapid acting insulin analog. Ann Pharmacother 34:1423-1431.
37. Hoffart V, Ubrich N, Lamprecht A, Bachelier K, Vigneron C, Lecompte T, Hoffman M, Maincent P. 2003. Microencapsulation of low molecular weight heparin into polymeric particles designed with biodegradable and nonbiodegradable polycationic polymers. Drug Deliv 10:1-7.
38. Moslemi P, Najafabadi AR, Tajerzadeh H. 2003. A rapid and sensitive method for simultaneous determination of insulin and A-21 desamido insulin by high performance liquid chromatography. J Pharm Biomed Anal 33:45-51.
39. Aprahamian M, Michel C, Humbert W, Devissaguet JP, Damgé C. 1987. Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. Biol Cell 61:69-76.
40. Damgé C, Michel C, Aprahamian M, Couvreur P, Devissaguet JP. 1990. Nanocapsules as carriers for oral peptide delivery. J Control Release 13:233-239.
41. Damgé C, Aprahamian M, Humbert W, Pinget M. 2000. Ileal uptake of polyalkylcyanoacrylate nanocapsules in the rat. J Pharm Pharmacol 52:1049-1056.
42. Pinto-Alphandary H, Aboubakar M, Jaillard D, Couvreur P, Vauthier C. 2003. Visualization of insulin-loaded nanocapsules: In vitro and in vivo studies after oral administration to rats. Pharm Res 20:1071-1084.
43. Bendayan M, Ziv E, Gingras D, Ben-Sasson R, Bar-On H, Kidron M. 1994. Biochemical and morphocytochemical evidence for the intestinal absorption of insulin in control and diabetic rats. Comparison between the effectiveness of duodenal and colon mucosa. Diabetologia 37:119-126.
44. Ziv E, Bendayan M. 2000. Intestinal absorption of peptides through the enterocytes. Microsc Res Tech 49:346-352.
45. Fernandez-Moreno MD, Serrano-Rios M, Prieto JC. 1987. Identification of insulin receptors in epithelial cells fromduodenum, jejunum, ileum, caecum, colon and rectum in the rat. Diabete Metab 13:135-139.
46. Kavimandan NJ, Peppas NA. 2008. Confocal microscopic analysis of transport mechanisms of insulin across the cell monolayer. Int J Pharm 354:143-148.
47. Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, Trüb T. 2000. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005.
48. Hajri A, Damgé C. 1998. Effects of cholecystokinin octapeptide on a pancreatic acinar carcinoma in the rat. Pharm Res 15:1767-1774.